Pidilizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | DLL1 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6424H9920N1704O2002S48 |
| Molar mass | 144594.83 g·mol−1 |
Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases.[1][2] Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, however, recent evidence suggests that Delta-like 1 (DLL1) is its primary binding target while binding to PD-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule.[3] Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.
- ^ Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, et al. (January 2014). "Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial". The Lancet. Oncology. 15 (1): 69–77. doi:10.1016/S1470-2045(13)70551-5. PMC 3922714. PMID 24332512.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Pidilizumab, American Medical Association- needs login.
- ^ Carroll J (26 January 2016). "Anti-PD-1? Well, no, says Medivation as a partial hold forces a halt to 'pivotal' cancer study". Fierce Biotech.